首页 > 市场调查报告书 > 医疗设备

医学影像诊断

市场调查报告书

商品编码

1410088

2023年至2028年临床试验影像市场预测

Clinical Trial Imaging Market - Forecasts from 2023 to 2028

出版日期: 2023年12月12日 | 出版商:

Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

全球临床试验影像市场预计在预测期内复合年增长率为 5.84%。

影像检查使医疗专业人员能够看到人体内发生的情况。这些测试将身体暴露于各种能源来源下，包括 X 射线、声波、放射性粒子和磁场。增加对研究计划的投资，为癌症和慢性肾臟病等长期疾病开发创新的医疗解决方案，是临床试验成像市场的主要成长要素。此外，由于这种疾病的高发病率和医疗保健成本的上升，对增强治疗解决方案的需求以及生物技术公司的崛起预计将进一步推动临床试验成像市场。

生技公司增加

越来越多专注于临床试验成像研究的生物技术公司预计将在未来几年推动临床试验成像市场的发展。例如，根据印度国家投资促进和便利化管理局的数据，2022年印度生物技术产业价值超过801.2亿美元，较2021年成长14%。此外，2022年印度生技研发领域投资约10亿美元。根据 AusBiotech Snapshot 2022，澳洲生物技术产业 2022 年较 2019 年成长 43%。此外，领先的生物技术公司和新兴企业（例如 BioTelemetry、WCG Clinical、CRISPR Therapeutics 和 10x Genomics）的存在进一步推动了临床试验成像市场的发展。

癌症患者增加

影像检查可用于分析癌症，因为癌症不仅获得生物学能力，而且常常表现出各种结构、生理和分子变化。因此，癌症病例的增加预计将扩大临床试验影像市场。例如，据世界卫生组织称，2020 年，六分之一的死亡者（即约 1000 万人）死于癌症，使其成为全球主要死亡原因。据估计，低收入和中等收入国家 30% 的癌症病例是由人类乳突病毒 (HPV) 和肝炎等致癌感染疾病引起的。对癌症治疗方法的探索仍在继续，新的分子标靶药物有望比标准化疗药物活性更高、毒性更小，从而带来更个体化的治疗。管理范式正在朝着越来越个体化的护理方向转变。

慢性病负担增加

慢性病是一种长期疾病，使全球无数人衰弱，因此临床试验影像对于早期疾病检测和早期治疗以确保及时介入至关重要。糖尿病、肾臟疾病和心血管疾病等慢性疾病的增加预计将推动临床试验影像市场的发展。例如，在美国，超过七分之一的成年人（即约 3700 万人）患有慢性肾臟病(CKD)（根据 NIDDK）。全球死亡的主要原因是心血管疾病（CVD）。预计 2019 年，CVD 将占全球死亡人数的 32%，死亡人数为 1,790 万人。根据世界卫生组织的数据，心臟病和中风占这些死亡人数的 85%。

该领域研究计划的增加

涉及影像临床试验的研究计划的增加也是临床试验影像市场的主要成长要素。例如，美国国家医学图书馆报告称，截至2022年4月，美国50个州和220个外国有410,319项入组研究，其中61,961项招募研究和169,924项药理学或生物学试验正在蔓延。此外，联合临床影像研究资源计划（U24s）由美国卫生署负责运营，该计划的重点是优化临床前和临床环境中精准医疗的定量成像方法。我们支持 10 个涉及各种治疗性介入和显像模式的合作临床试验计划。

北美地区预计将大幅成长

预计在预测期内，北美地区将在临床试验成像市场中占据重要份额。因素包括医疗保健支出的增加、慢性病的流行以及老年人口的增加。例如，根据英联邦组织的数据，2021年美国医疗保健系统占GDP的17%，远高于其他地区。此外，医疗保健领域的技术进步和政府资助的专家研究也有望进一步扩大市场规模。 Medpace 等市场领导的出现预计将进一步推动临床试验影像市场的发展。

主要市场参与者

IXICO 是一家总部位于英国的医学影像服务供应商，致力于改善中枢神经系统临床试验的结果。透过其可远端存取的 Trial Tacker 技术，该公司将于 2022 年 9 月建立并实施突破性的机器学习 AI资料分析，以帮助製药公司提高药物研究的投资收益，并降低临床试验期间风险的降低。 Navitas Life Sciences 是一家印度药物开发和临床研究公司，总部位于班加罗尔。该公司的主协议可提高肿瘤临床试验的成功率并以更低的成本更快地识别失败。它也符合美国FDA 创造安全药物的目标。 Resonance Health 是一家总部位于奥地利的医疗技术公司，专注于非侵入性医学影像分析的开发和商业化。我们提供铁过量、代谢性疾病、肝臟相关疾病、脑部疾病等检测CRO服务和影像诊断服务。

市场主要发展

2023 年 3 月，Clario 为 CRO 推出了最先进的云端基础的影像检视器工具。这使得 CRO 能够透过直觉的基于网路的影像检视器近乎即时地读取高品质影像。 2023年1月，Cellac Imaging开发的混合伽玛光学相机被引进美国临床试验程序。辐射用于对给予患者的放射性同位素进行成像。它还可用于骨骼、肾臟和感染疾病、淋巴结成像和定位前哨淋巴。 2022 年 11 月，VIDA Diagnostics 推出了其人工智慧支援平台的更新，称为 VIDA Intelligence 2.0，以提高临床试验成像的效率。透过数位入职简化临床试验参与者的註册流程。

介绍
北美洲
- 美国
- 加拿大
- 墨西哥
南美洲
- 巴西
- 阿根廷
- 其他的
欧洲
- 英国
- 德国
- 法国
- 西班牙
- 其他的
中东/非洲
- 沙乌地阿拉伯
- 阿拉伯聯合大公国
- 以色列
- 其他的
亚太地区
- 日本
- 中国
- 印度
- 韩国
- 印尼
- 泰国
- 其他的

第九章竞争环境及分析

主要企业及策略分析
新兴企业和市场盈利
合併、收购、协议和合作
供应商竞争力矩阵

第十章公司简介

IXICO plc
Navitas Life Sciences
Resonance Health
ProScan Imaging
Radiant Sage LLC
Medpace
Cardiovascular Imaging Technologies
WCG Clinical
BioTelemetry
Median Technologies

简介目录

Product Code: KSI061615767

The global clinical trial imaging market is estimated to grow at a CAGR of 5.84% during the forecast period.

An imaging exam allows medical professionals to view what is happening inside the human body. These exams expose the body to various sources of energy, such as X-rays, sound waves, radioactive particles, or magnetic fields. The increasing investment in research projects to develop innovative medical solutions for long-lasting diseases such as cancer, chronic kidney disease, and others are major growth factors in the clinical trial imaging market. Moreover, the higher prevalence of this disease and demand for enhanced treatment solutions along with the emerging biotechnology companies due to rising healthcare expenditure are further contemplated to boost the clinical trial imaging market.

Increasing Biotechnological Companies

The increasing number of biotechnology companies with a focus on clinical trial imaging studies is expected to boost the clinical trial imaging market in the coming years. For instance, the Indian biotechnology industry crossed $80.12 billion in 2022 which is a 14% increase from 2021 as per the National Investment Promotion & Facilitation Agency, India. Moreover, around $1 billion was invested in the biotechnology R&D sector of India in 2022. The Australian biotechnology sector showed a 43% increase in 2022 from 2019 as per the AusBiotech Snapshot 2022. Moreover, the presence of leading biotechnology companies and emerging companies such as BioTelemetry, WCG Clinical, CRISPR Therapeutics, and 10x Genomics among others are further driving the clinical trial imaging market.

Increasing Cancer Cases

Imaging tests can be used to analyze cancers since they frequently exhibit a variety of structural, physiologic, and molecular changes as well as acquired biological abilities. Therefore, the rising cancer cases are contemplated to augment the clinical trial imaging market. For instance, one in six deaths, or around 10 million deaths, was due to cancer in 2020, making it the top cause of death globally as per the WHO. In low and lower-middle-income nations, cancer-causing infections including the human papillomavirus (HPV) and hepatitis are estimated to be the cause of 30% of cancer cases. The promise of novel targeted medicines with more focused action and reduced toxicity compared to standard chemotherapeutics is altering the management paradigm towards more tailored treatment and individualized care as the search for a cancer cure continues.

Growing Burden of Chronic Diseases

Chronic disease is a long-lasting condition that deteriorates a huge number of people on earth therefore, clinical trial imaging is crucial in earlier detection and treatment of disease as it ensures timely intervention. The rising cases of chronic diseases such as diabetes, kidney disease, cardiovascular diseases, and several others are expected to drive the clinical trial imaging market. For instance, More than one in seven adults in the United States, or around 37 million people, suffer from chronic kidney disease (CKD) as per the NIDDK. The primary cause of death in the world is cardiovascular disease (CVD). 32% of all fatalities worldwide in 2019 were predicted to have been caused by CVDs, killing 17.9 million individuals. Heart attack and stroke caused 85% of these fatalities according to the WHO.

Increasing Research Projects in the Field

The rising research projects including imaging clinical trials are another major growth driver in the clinical trial imaging market. For instance, the US National Library of Medicine reported that as of April 2022, there were 410,319 registered research spread throughout all 50 US states and 220 international locations, including 61,961 recruitment studies and 169,924 pharmacological or biological trials. Moreover, the Co-Clinical Imaging Research Resources Program (U24s) is run by the US Department of Health to focus on the optimization of quantitative imaging methods for precision medicine in preclinical and clinical settings. It supports ten co-clinical trial projects spanning a diverse range of therapeutic interventions, and imaging modalities.

North America is Expected to Grow Significantly

The North American region is projected to hold a significant share of the clinical trial imaging market during the forecasted period. Various factors attributed to such a share are increasing healthcare expenditure, the prevalence of chronic diseases, and the growing older population. For instance, the healthcare system in the US contributed 17% of GDP in 2021 which is way higher than other regions as per the Common Wealth Organization. Additionally, technological advancements and government-backed research in healthcare by experts are further expected to propel the market size. The presence of market leaders such as Medpace is further anticipated to boost the clinical trial imaging market.

Major Market Players

IXICO is a UK-based medical imaging services provider to enhance the outcomes of CNS trials. Through its remote access Trial Tacker Technology, the company created and implemented a ground-breaking machine learning AI data analytics in September 2022 to increase the pharmaceutical clients' return on investment in drug research and lower risk during clinical trials.
Navitas Life Sciences is an Indian drug development and clinical research company based out of Bengaluru. Master Protocol offered by the company increases the success rate and recognizes failure faster and at a lower cost in oncology clinical trials. It is also consistent with the US FDA's goal of helping and making safe drugs.
Resonance Health is an Austalia-based medical technology company with a focus on the development and commercialization of non-invasive medical imaging analysis. It provides laboratory CRO services and imaging services for iron overload disorders, metabolic disorders, liver-related disorders, and brain diseases.

Key Market Developments

In March 2023, a state-of-the-art cloud-based image viewer tool was introduced by Clario for CROs to use to view the images of their clinical trials. It enables CROs to read quality images in near real-time through an intuitive web-based imaging viewer.
In January 2023, a hybrid gamma optical camera developed by Serac Imaging was introduced in clinical trial procedures in the US. It uses radiation to image radioisotopes which are administered to the patients. It also helps in bone, renal, and infection imaging, lymphatic imaging, and sentinel lymph localization.
In November 2022, VIDA Diagnostics launched an updated artificial intelligence-enabled platform named VIDA Intelligence 2.0 to enhance clinical trial imaging efficiencies. It simplifies the participant's enrolment process for clinical trials through digital onboarding.

Segmentation

By Service

Clinical Trial Design & Consultation Services
Reading & Analytical Services
Operational Imaging Services
System & Technology Support Services
Project & Data Management

By Application

NASH
CKD
Diabetes
Cardiovascular Diseases
Musculoskeletal
Oncology
Gastroenterology
Pediatrics
Others

By End-Use

Biotechnology & Pharmaceutical companies
Medical Devices Manufacturers
Academic & Government Research Institutes
Contract Research Organizations (CROs)
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. CLINICAL TRIAL IMAGING MARKET, BY SERVICE

5.1. Introduction
5.2. Clinical Trial Design & Consultation Services
5.3. Reading & Analytical Services
5.4. Operational Imaging Services
5.5. System & Technology Support Services
5.6. Project & Data Management

6. CLINICAL TRIAL IMAGING MARKET, BY APPLICATION

6.1. Introduction
6.2. NASH
6.3. CKD
6.4. Diabetes
6.5. Cardiovascular Diseases
6.6. Musculoskeletal
6.7. Oncology
6.8. Gastroenterology
6.9. Pediatrics
6.10. Others

7. CLINICAL TRIAL IMAGING MARKET, BY END-USE

7.1. Biotechnology & Pharmaceutical companies
7.2. Medical Devices Manufacturers
7.3. Academic & Government Research Institutes
7.4. Contract Research Organizations (CROs)
7.5. Others

8. CLINICAL TRIAL IMAGING MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others